linjc16/ctgov huggingface dataset:
Robot-assisted Lobectomy Versus Video-assisted Lobectomy

Study Overview
=================
Brief Summary
-----------------
This prospective and observational cohort studies the morphine consumption difference during the first 48 hours after a lung lobectomy between patients operated with a robot assisted or a video-assisted technique for a lung cancer lobectomy. Second outcome was to search eventual cardiac output difference during the surgery in 100 patients (50 in each group) using a non invasive monitoring device of cardiac output All patients operated between january 2016 and March 2017 for a lung cancer lobectomy were included.

Official Title
-----------------
Robot-assisted Lobectomy Versus Video-assisted Lobectomy : a Prospective Observational Study

Conditions
-----------------
Robotic Surgical Procedures, Pneumonectomy; Status, Anesthesia and Analgesia, Cardiac Output

Intervention / Treatment
-----------------
* Drug: Morphine
* Other: Cardiac output measure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers Mono lobectomy of lung for early stage cancer (T2Nx and earlier) Video or robot assisted procedure Exclusion Criteria: Advanced stage of cancer (T3Nx and greater) Need of thoracotomy conversion during procedure Morphine intolerance or addiction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| video-assisted lobectomy group<br>patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure | Drug: Morphine<br>* we observe the self-patient controlled morphine consumption during the first 48h after surgery<br>Other: Cardiac output measure<br>* we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )<br>|
| robot-assisted lobectomy group<br>patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure | Drug: Morphine<br>* we observe the self-patient controlled morphine consumption during the first 48h after surgery<br>Other: Cardiac output measure<br>* we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morphine consumption | morphine consumption for each patient using a self patient - controled morphine pump | 48 hours after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac output | continuous cardiac output during surgery procedure | during 30 minutes after incision and optic introduction |
Medication Optimisation for Reducing Events in a Private Practice Setting

Study Overview
=================
Brief Summary
-----------------
Using a prospective study design of two three month periods (before and after genotyping) in which the patients will self-monitor their health status and possible medical events it is hypothesized that it will be shown that patients having their medication altered to fit their genetic status and/or having their medication altered because of inherent interaction potential will have less recordable events after genotyping and medical analysis than before. It is well known that ADRs (recordable adverse events to medication) are responsible for a large number of deaths and hospitalizations. Furthermore it is well recorded that genotyping of individual cytochrome P450 enzymes (2D6, 2C9, 2C19, among others) is directly related to a metabolic phenotype - fast metabolisers, slow metabolisers, intermediate and normal metabolisers. These differing phenotypes have altered metabolism of many medications and in a number of retrospective clinical trails it has been shown that ADRs and effect can be reduced/bettered through genotyping and alteration of medication.

Official Title
-----------------
Observational Study of the Pharmaco-Economic and Medical Effects of Optimising Medication Using Pharmacokinetic Pharmacogenomics and Medication Interaction Analysis in Private Practice.

Conditions
-----------------
Pharmacogenetic Analysis to Reduce Events.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 18 years not demented 1 or more documented events in the previous 6 months. more than one medication multi-morbid Exclusion Criteria: demented life expectancy less than 1 year heart attack within the last 6 months Marcumar® Therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of reported events in the time frame. |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of total costs associated per patient in the time frame. |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pharmacogenetics, pharmacoeconomics, adverse events, drug metabolism
Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects

Study Overview
=================
Brief Summary
-----------------
Patients suffering from Thalassemia or another hemoglobinopathies required regular blood transfusions. The complications and adverse effects of blood transfusions can be classified as immediate and late. Among the immediate effects the most common are allergic reactions and fever, besides congestive heart failure in patients with cardiomyopathy. The late effects are mostly related to blood transmitted infections like HIV or Hepatitis C infections. The purpose of this study is to summarize the data of those complications in a cohort of 100 patients receiving regular blood transfusion.

Detailed Description
-----------------
About 100 patients aged several months to 50 years are treated in the Pediatric Hematology Unit, most of those patients receive blood transfusions monthly. The adverse reactions were routinely recorded during each transfusion. All the patients were also screened annually for the incidence of blood transmitted infections principally HIV and Hepatitis C. All those records will be systematically screened and all the immediate or late adverse reactions and complications related to blood transfusions will be summarized. A second goal of this study will be to control the staff strictness related to the ministry of health protocol dealing to blood transfusions.

Official Title
-----------------
Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects.

Conditions
-----------------
Thalassemia, Sickle Cell Anemia

Intervention / Treatment
-----------------
* Other: Clinical medical record summary


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving blood transfusions due to chronic hematologic disorders Exclusion Criteria: Not applicable

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients receiving blood transfusions<br>All the patients with blood disorders that require blood transfusions | Other: Clinical medical record summary<br>* Summary of immediate and late adverse effects of blood transfusions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood transfusions, Adverse events, Hepatitis C, HIV
A Study of Visual Attention Training to Improve Balance and Mobility

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if training visual attention improves balance and mobility, and reduces falls in older adults.

Detailed Description
-----------------
Visual training in visual attention is compared with activity as usual.

Official Title
-----------------
A Study of Visual Attention Training to Improve Balance and Mobility

Conditions
-----------------
Accidental Falls

Intervention / Treatment
-----------------
* Other: Visual training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy older adults Visual acuity 6/12 or better able to speak English Exclusion Criteria: No known dementia or cognitive impairment not dependent on a walker or cane

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Visual training<br>Training in visual attention | Other: Visual training<br>* 6 training sessions with computerised visual attention paradigm<br>|
| Placebo Comparator: Usual activity<br>Usual activity | Other: Visual training<br>* 6 training sessions with computerised visual attention paradigm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Balance on force plate platform | Standard deviation of the medial lateral (ML) and anterior posterior (AP) center of pressure, ML and AP CoP maximum sway, ML and AP CoP range in each direction (range = maximum excursion - minimum excursion) and the cumulative path length in cms | after 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mini-BESTest (Balance evaluation) | 14 short balance tests divided under four domains of balance control; 1) anticipatory body control, 2) reactive postural control, 3) sensory orientation and 4) balance during dynamic gait | after 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Falls, Older adults, Balance, Mobility, Visual attention
High Resolution Digital Imaging of the Uterine Cervix

Study Overview
=================
Brief Summary
-----------------
This study was designed to gather digital pictures of the cervix and correlate it to its histopathology, and then use those relationships to teach a computer how to objectively find cervical dysplasia and cancer.

Official Title
-----------------
Investigation to Correlate High Resolution Digital Images of the Uterine Cervix With Histopathology

Conditions
-----------------
Colposcopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Negative pregnancy test 18 years and older Presence of a cervix Exclusion Criteria: Pregnant Absence of a cervix Less than 18 years old Male

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colposcopy
Calgary Registry for Advanced and Therapeutic Endoscopy

Study Overview
=================
Brief Summary
-----------------
The aim of the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is to be a high-fidelity prospective multi-centre registry. The study population consists of consecutive adult ERCP patients from September 2018 to August 2022. Informed consent is acquired for each patient. All relevant pre-procedural, procedural, peri-procedural and post-procedural data are captured in real time by a full-time third-party research assistant directly observing procedures. Outcomes are ascertained by comprehensive medical record review and patient phone interview 30 days after the index procedure. This registry also serves as a secure data collection platform for several currently recruiting prospective studies and randomized trials.

Official Title
-----------------
Calgary Registry for Advanced and Therapeutic Endoscopy

Conditions
-----------------
Biliary Disease, Pancreatic Diseases

Intervention / Treatment
-----------------
* Procedure: Endoscopic retrograde pancreatography (ERCP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any standard indication for ERCP, in the absence of standard contraindications; age 18 years or over; ability and willingness to give informed consent to be included in the registry and/or to involvement in one (or more) prospective sub-studies, or accompaniment by a surrogate who is willing and able to provide consent. Exclusion Criteria: -none other than inverses of above.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endoscopic retrograde pancreatography (ERCP)|Endoscopic procedure to access biliary and/or pancreatic structures|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of unplanned healthcare utilization | Composite outcome of post-ERCP pancreatitis, bleeding, cholangitis or sepsis, or any other adverse event deemed related to the index procedure, or emergency department presentation or inpatient admission within 30 days deemed related to the index procedure. | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of post-ERCP pancreatitis | Typical abdominal pain with amylase/lipase 3 times normal or higher | 30 days | 
| Rate of post-ERCP bleeding | Hematemesis and/or melena or hemoglobin drop 2 g or greater | 30 days | 
| Rate of post-ERCP cholangitis or sepsis | Fever > 38C for 24 hours or more with cholestasis, or positive blood cultures | 30 days | 
| Technical success rates |  | Immediate |
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer

Study Overview
=================
Brief Summary
-----------------
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate whether myocardial damage as measured with T1 / T2 Cardiovascular Magnetic Resonance (CMR) mapping and plasma hs-Troponin T is related to changes in GLS.

Official Title
-----------------
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer

Conditions
-----------------
Cardiotoxicity, Breast Cancer, Chemotherapy Induced Systolic Dysfunction

Intervention / Treatment
-----------------
* Diagnostic Test: CMR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Age ≥ 18 years A diagnosis of primary breast cancer Starting (neo-) adjuvant chemotherapy treatment within 2 months after screening Cardiotoxicity risk score of intermediate, high or very high risk Exclusion Criteria: Previous radiotherapy or systemic cancer treatment Cancer metastasis Life expectancy of less than 6 months History of myocardial infarction or heart failure Known contra-indications for CMR Refusal or inability to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CMR|GLS measurement with CMR|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global Longitudinal Strain (GLS) change after chemotherapy compared to baseline | A relative reduction in Global Longitudinal Strain (GLS) assessed with CMR | Baseline and 2 weeks after the last chemotherapy cycle |
Whole Body Washing With Chlorhexidine for the Eradication of MRSA

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether whole body washing with chlorhexidine in combination with mupirocine nasal ointment is effective in the eradication of meticillin-resistant Staphylococcus aureus (MRSA).

Detailed Description
-----------------
The number and rate of infections due to meticillin-resistant Staphylococcus aureus (MRSA)is increasing world wide. Patients who are colonized with MRSA are the main source for further distribution. In addition colonization with MRSA is a precondition for infection. Whole body washing with antiseptic solutions as part of eradication strategies for MRSA has been widely used. However, there is insufficient evidence to support use of topical antimicrobial therapy for eradicating of MRSA because treatment with antiseptic solution has never been compared to placebo. Comparison: The efficacy of whole body washing in the control of MRSA was studied in a randomized, placebo-controlled, double-blinded clinical trial. The study treatment consisted of five days of whole body washing either with 4% chlorhexidine solution (verum) or with placebo. All patients received mupirocin nasal ointment and chlorhexidine mouth rinse. The outcome was evaluated 3, 4, 5, 9 and 30 days after treatment by swabs taken from several body site.

Official Title
-----------------
The Value of Whole Body Washing With Chlorhexidine for the Eradication of MRSA - a Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Conditions
-----------------
MRSA-Colonization

Intervention / Treatment
-----------------
* Drug: Chlorhexidine solution 4%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: persons who are colonized with MRSA, i.e. one or more cultures from any body site yielded MRSA Exclusion Criteria: ongoing systemic or local antimicrobial treatment directed against MRSA hypersensitivity to mupirocin or chlorhexidine pregnancy previous enrolment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Chlorhexidine solution 4%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy of a whole body treatment with chlorhexidine in eradicating overall MRSA carriage |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of MRSA infection |  |  | 
| tolerance to the antiseptic whole body treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRSA, eradication, chlorhexidine
Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus Optical Coherence Tomography (OCT)

Study Overview
=================
Brief Summary
-----------------
The Cirrus HD OCT, a new spectral domain optical coherence tomography (OCT), has better resolution than the previous time domain Stratus OCT. Discriminating ability of these two OCTs for diagnosis of glaucoma and judgement of disease progression will be studied.

Detailed Description
-----------------
The Cirrus HD OCT is a new spectral domain OCT. Even though its resolution and speed are much better than the previous time domain Stratus OCT, its diagnostic power for glaucoma detection and judgement of disease progression should be directly compared with Stratus OCT. In the present study, we will review the data of peripapillary retinal nerve fiber layer thickness measurement using the Cirrus HD OCT and Stratus OCT. Their discriminating ability for diagnosis of glaucoma and judgement of disease progression will be compared using the ROC curves and Cohen's kappa.

Official Title
-----------------
Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus OCT

Conditions
-----------------
Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Retinal nerve fiber layer analysis with Cirrus OCT and Stratus OCT within 1 month Exclusion Criteria: Intraocular surgeries history DM High refractive error ( < -4.00 diopters, or > + 4.00 diopters) Media opacity

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Defined glaucoma patients | |
| 2<br>Glaucoma suspects and normal controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal nerve fiber layer thickness |  | When the OCT images are taking | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual field |  | When the OCT images are taking | 
| Red-free fundus photo |  | When the OCT images are taking | 
| Intraocular pressure |  | When the OCT images are taking | 
| Central corneal thickness |  | When the OCT images are taking | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Retinal nerve fiber layer, Cirrus OCT, Stratus OCT